IMNMImmunome, Inc.
$18.00+9.1% 1Y
$18.00
$15.2452 weeks$29.84
Is the price fair?
What IMNM's price assumes
Immunome, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 182× revenue.
182
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 4.57
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 4.57
- EV / EBIToperating margin −2052%: the multiple describes the denominator
- not meaningful
- Market capitalisation113.6 million shares, counted Aug 6, 2026
- $2.04B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks